KAT2B and neoplasm: Surgically removed PDAC patient tumour samples from consenting patients were confirmed by histologists before further processing for 1) confirming the enrichment of CSC marker CD133, CD44 and SSEA4 expression upon Gemcitabine chemotherapy reagent treatment; 2) effects of WNT/β-catenin inhibition with IWR and its effect on CSCs; 3) the effects of GCN5 inhibitors GSK4028 and L-Moses on CSCs as single treatment and in combination with currently used chemotherapy reagent Gemcitabine.